Compare Cassava Sciences Inc (FLNA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Tempus AI — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Tempus AI trades at $52.75 (market cap $10.28B). The key difference: Tempus AI is far larger — about 193.5× Cassava Sciences Inc's market cap, and Tempus AI is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TEM | |
|---|---|---|
Market Cap | $53.14M | $10.28B |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $103.25 |
52-Week Low | $1.09 | $42.37 |
Enterprise Value | -$33.43M | $10.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Tempus AI (TEM) trades at $53.69, down 8.39% over 24 hours, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth ($1.27B in 2025) and consistent earnings beats, but remains unprofitable with negative net income margins (-22.2%). Recent news highlights AI deployment in healthcare systems and FDA clearances, supporting its data-driven healthcare platform.
The outlook balances high-growth potential in AI healthcare data against persistent profitability challenges. Analyst consensus is bullish with a $68.50 price target, but investors face risks from ongoing cash burn, competitive pressures, and execution hurdles as the company scales its platform toward sustainable margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
